Biotech · Private company
Qurient Co., Ltd.
Track this companyFree. Adds Qurient Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- FulvestrantPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- KEYTRUDA® (pembrolizumab)Phase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- Mocaciclib (Q901)Phase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Q301 CreamPhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Q702Phase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Q702Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 12, 2025ClinicalTrials.gov NCT06445907 · fetched Nov 12, 2026
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 12, 2023ClinicalTrials.gov NCT05438420 · fetched Nov 12, 2026
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Aug 30, 2022ClinicalTrials.gov NCT05394103 · fetched Nov 12, 2026
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid TumorPHASE1 · COMPLETED · started Nov 18, 2020ClinicalTrials.gov NCT04648254 · fetched Nov 12, 2026
- Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis PatientsPHASE2 · COMPLETED · started Jun 21, 2018ClinicalTrials.gov NCT03571620 · fetched Nov 12, 2026